Quick access to up-to-date company information.
STIOLTO™ RESPIMAT® Now Available in the United States for the Treatment of COPD
Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
Phase I Data Published in The Lancet Show Boehringer Ingelheim’s Idarucizumab* Reverses Anticoagulant Effects of Dabigatran
Boehringer Ingelheim Statement on Proposed CT Tax Increases
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877